Olaparib is a revolutionary treatment for patients with ovarian and breast cancer. Currently, there is no established 1-day drug desensitization protocol for patients with olaparib type-1 hypersensitivity reactions despite well documented IgE-mediated adverse reactions occurring with olaparib. We report a 58-year-old female with immediate, reproducible IgE-mediated adverse reactions to olaparib tablets with implementation of a 1-day novel desensitization protocol to olaparib. Following desensitization, the patient was successfully transitioned from olaparib capsules to tablets with no loss of tolerance. To our knowledge, this is the first reported case of successful olaparib desensitization using a novel 1-day desensitization protocol, and will contribute to drug allergy knowledge, in an area where robust data is lacking. This case demonstrates the important role for drug desensitization in patients with immediate hypersensitivity reactions to chemotherapeutic agents. Furthermore, as olaparib capsules are being phased out in favour of olaparib tablets, we provide a clear case that transitioning from capsule to tablet form did not cause a loss of tolerance.

中文翻译：

---

使用新型一日协议成功完成奥拉帕尼脱敏

Olaparib是卵巢癌和乳腺癌患者的革命性疗法。尽管奥拉帕尼发生IgE介导的不良反应，但目前尚无针对奥拉帕尼1型超敏反应患者的既定一日药物脱敏方案。我们报告了一名58岁女性，对olaparib实施了为期1天的新型脱敏方案，对olaparib片剂具有即时，可再现的IgE介导的不良反应。脱敏后，患者成功地从olaparib胶囊转变为片剂，并且没有丧失耐受性。据我们所知，这是首次报告的使用新型1天脱敏方案成功进行olaparib脱敏的案例，在缺乏可靠数据的领域，这将有助于药物过敏知识。该病例证明了在对化学治疗剂立即发生超敏反应的患者中，药物脱敏的重要作用。此外，随着奥拉帕尼胶囊逐渐被奥拉帕尼片淘汰，我们提供了一个明确的案例，即从胶囊到片剂的转变不会引起耐受性的下降。